Cephalon expands site in Nevers, France

US drugmaker Cephalon has begun to expand the facilities at its Nevers site in France. The move is part of a larger operation to develop the three sites that it owns in the country which it acquired following its takeover of Lafon. Cephalon is doubling capacity at Nevers based on the use of lyophilization technology which promotes instant dispersion of the drug product on contact with saliva. Some 16.0 million euros ($22.5 million) is being spent on a line to produce up to 33 million blisters a year for the world market. The wider operation will cost 80.0 million euros, the firm noted.